Trastuzumab (Herceptin) is used in treatment of:
Alemtuzumab humanized IgG1 mAb 150 kDa directed CD52 glycopeptide 21-28 kDa GPI-anchored highly expressed 500k copies normal malignant B T lymphocytes monocytes macrophages eosinophils dendritic cells but absent HSC permitting immune reconstitution after depletion absent neutrophils limiting neutropenia. CD52 function incompletely understood proposed T-costimulation binding Siglec-10 inhibitory modulating migration L-selectin. Binding clusters GPI protein lipid rafts inducing proximity Fc enabling C1q multivalent binding activating classical complement C4 C2 cleavage forming C3 convertase C4b2
Ref: Hale 1983 Transplantation Alemtuzumab CD52 Expression; FDA Campath Lemtrada Label CD52 Depletion; Janeway CD52 Depletion Reconstitution Chapter 14.